Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 9Nivolumab 4Fluorouracil 4Mohs Surgery 3talimogene laherparepvec 2atezolizumab 2Therapeutics 2Photochemotherapy 2Petrolatum 2Paclitaxel 2Niacinamide 2Aminolevulinic Acid 2tozuleristide 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1selinexor 1regorafenib 1peginterferon alfa-2b 1peginterferon alfa-2a 1osimertinib 1nanocis 1methyl 5-aminolevulinate 1fludarabine 1daromun 1cobimetinib 1cemiplimab 1avelumab 1aldesleukin 1aflibercept 1afamelanotide 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × tozuleristide × Dermatologic × Clear all
NCT02097875 2015-04-21

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Blaze Bioscience Australia Pty Ltd

Phase 1 Completed
21 enrolled
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡